MyChoice® CDx Plus

HRD Companion Diagnostic Test

Identify the right ovarian cancer patients for PARPi treatment in time

Myriad genetics

Missing out on a PARPi eligible woman

Finding women with HRD+ is complex

- In the early setting, ovarian cancer will progress in 7 out of 10 women.[1]
- PARP inhibitors can slow down, potentially cure the disease, and help these women live longer. This works best for women with a certain type of ovarian cancer known as HRD+.[2,3]
- One in four of these women have a change in their *BRCA1/2* genes. But 10% of these changes cannot be found by tests that look for inherited changes.[4]

For about half of the women with HRD+ we are not able to determine their status by looking at each possible cause one by one.[5]



Optimizing HRD status evaluation

Combining multiple factors

- *BRCA* status and Genomic Instability Score combined identifies more women with a HRD+ tumor than any other test.
- *BRCA1* and *BRCA2* status is determined by changes in the sequence variants and identification of large rearrangements in the genes.
- The Genomic Instability Score is calculated based on the loss of heterozygosity, the telomeric imbalance, and large-scale transitions within the entire genome.

By combining these factors, you can find up to 3.5 times more patients with HRD+ than *BRCA* germline tests.[6]



Introducing MyChoice

Make sure that you don't miss a HRD+ patient

By combining tumor *BRCA* mutation testing and Genomic Instability Score, MyChoice identifies more patients eligible for PARP inhibitor treatment.

Identifying the tumor *BRCA1* and *BRCA2* status

MyChoice identifies and classifies *BRCA1/2* sequence variants and large rearrangements as well as somatic and germline variants present in the tumor.

MyChoice® CDx Plus

HRD Companion Diagnostic Test

Tumor *BRCA* and Genomic Instability Score factors into final HRD status

Genomic Instability Score status & **Tumor *BRCA* status** » **Myriad Genetics HRD status**

Genomic Instability Score status	Tumor *BRCA* status	Final Myriad Genetics HRD status
Positive	Negative	Positive
Positive	Positive	Positive
Negative	Positive	Positive
Negative	Negative	Negative

MyChoice provides a clear HRD status

Despite the very complex technology utilised, MyChoice gives you an easy to interpret result report for a clear HRD Status: positive or negative.

Assessing the Genomic Instability Score (GIS)

The GIS status is calculated with LOH (loss of heterozygosity), TAI (telomeric alleic imbalance), and LST (large-scale transitions) in the entire genome.

Get the results in 2-3 weeks

MyChoice delivers results in 2-3 weeks to aid you in making informed treatment decisions in a timely manner for your patients.

MyChoice HRD status includes *BRCA* & GIS

By looking at both the cause *(BRCA)* and the consequence (GIS) of the HRD status, MyChoice is the most comprehensive test available.

First-in-class HRD test

Mentioned in major guidelines...

ESMO

European Society of Medical Oncology

Validated scar-based HRD tests can be used to guide PARP inhibitor treatment. ESMO recognizes MyChoice CDx is the only scar based HRD test validated in the first-line maintenance setting.[7]

ASCO

American Society of Clinical Oncology

Myriad MyChoice CDx is included in the new recommendations from The American Society of Clinical Oncology (ASCO) on the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.[8]

NCCN

National Comprehensive Cancer Network®

Somatic testing should prioritize identification of molecular alterations that inform the use of effective interventions. This includes assessing BRCA1/2, loss of heterozygosity (LOH), or homologous recombination deficiency (HRD) status in the absence of a germline BRCA mutation.[9]

Superior to other solutions

		Many other HRD solutions	MyChoice
***BRCA1 & BRCA2* status**	Sequence variants	✓	✓
	Large rearrangement	⊘	✓
Prospectively validated genomic instability status	Loss of heterozygosity (LOH)	⊘*	✓
	Telomeric allelic imbalance (TAI)	⊘	✓
	Large-scale state transition (LST)	⊘	✓

* One commercially available test with prospectively validated %LOH

Not all tumor tests detect large rearrangements

MyChoice CDx conducts a comprehensive assessment of LOH, TAI, and LST across the entire genome

...with Level of Evidence 1A

PAOLA The Phase III PAOLA-1/ENGOT-ov25 trial evaluated maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer.[2]

Progression-free survival (PFS) in patients with HRD after 5 years median follow-up[10]

59% **Reduction in risk of disease progression or death**



Final overall survival (OS) in patients with HRD after 5 years median follow-up[10]

38% **Reduction in risk of death** for olaparib + bevacizumab vs bevacizumab alone



PRIMA The Phase III PRIMA study evaluated niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer after a response to first-line, platinum-based chemotherapy.[3]

Progression-free survival in patients with HRD with 3.5 years median follow-up[11]

48% **Reduction in risk of disease progression or death**



MyChoice® CDx Plus

HRD Companion Diagnostic Test

How to access MyChoice CDx Plus

Download request form MyChoice lab

Send MyChoice CDx Plus request to your lab

Your lab send tissue to MyChoice lab

MyChoice lab analyses tissue

Result report is sent to you and your lab

Myriad Genetics is committed to illuminating the treatment pathway for every woman

Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling doctors to better detect, treat and prevent disease.

Myriad discovers and provides genetic and genomic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and provide access to the right treatments.

References:

1. Ledermann, J. et al. Annals Of Oncology 2013 2. Ray-Coquard, I. et al. New England Journal Of Medicine 2019 3. Gonzalez-Martin, A. et al. New England Journal Of Medicine 2019 4. The Cancer Genome Atlas Research Network. Nature 2011 5. Watkins, J. A. et al. Breast Cancer Research 2014 6. Timms, K. M. et al. Journal of Clinical Oncology 2020 7. Miller R. E. et al. Annals of Oncology 2020 8. Tew W. P. et al. Journal of Clinical Oncology 2020 and 2022 9. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer V.1.2023 10. Ray-Coquard I. et al. Annals of Oncology 2023 11. Gonzalez-Martin, A. et al. European Journal of Cancer 2023.

Myriad genetics

CE IVD

Myriad Genetic Laboratories, Inc.
320 Wakara Way
Salt Lake City, Utah 84108
PH: +1 (877) 283-6709
FX: +1 (801) 883-8998
www.myriad.com

EC REP

Myriad International GmbH
Nattermannallee 1
50829 Cologne, Germany

Outside U.S.A
Email: CustomerSupport@myriadgenetics.eu

The Myriad Genetics MyChoice® CDx Plus test was developed and performance characteristics were determined by Myriad Genetic Laboratories, Inc. and in compliance to In-Vitro Diagnostic Device Directive (98/79/EC) and is CE marked. Myriad is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Myriad is compliant with multiple international standards including, ISO 13485:2016 and ISO 15189: 2012 as applicable.

MYC_MD_SHORT_BRO_07_23_EN